{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:29:02Z","timestamp":1753892942712,"version":"3.41.2"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T00:00:00Z","timestamp":1701129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:p>While medical countermeasures in COVID-19 have largely focused on vaccinations, monoclonal antibodies (mAbs) were early outpatient treatment options for COVID-positive patients. In Minnesota, a centralized access platform was developed to offer access to mAbs that linked over 31,000 patients to care during its operation. The website allowed patients, their representative, or providers to screen the patient for mAbs against Emergency Use Authorization (EUA) criteria and connect them with a treatment site if provisionally eligible. A validated clinical risk scoring system was used to prioritize patients during times of scarcity. Both an ethics and a clinical subject matter expert group advised the Minnesota Department of Health on equitable approaches to distribution across a range of situations as the pandemic evolved. This case study outlines the implementation of this online platform and clinical outcomes of its users. We assess the impact of referral for mAbs on hospitalizations and death during a period of scarcity, finding in particular that vaccination conferred a substantially larger protection against hospitalization than a referral for mAbs, but among unvaccinated users that did <jats:italic>not<\/jats:italic> get a referral, chances of hospitalization increased by 4.1 percentage points.<\/jats:p>","DOI":"10.3389\/fpubh.2023.1226935","type":"journal-article","created":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T05:36:19Z","timestamp":1701149779000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Using a web platform for equitable distribution of COVID-19 monoclonal antibodies: a case study in resource allocation"],"prefix":"10.3389","volume":"11","author":[{"given":"Jonathon P.","family":"Leider","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debra","family":"DeBruin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra T.","family":"Waterman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umesh","family":"Ghimire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haley","family":"Huhtala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary","family":"Zirnhelt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Lynfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John L.","family":"Hick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,28]]},"reference":[{"volume-title":"Coronavirus (COVID-19) update: FDA authorizes monoclonal antibody for treatment of COVID-19","year":"2020","key":"ref1"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"e440","DOI":"10.1093\/cid\/ciab912","article-title":"A randomized, placebo-controlled clinical trial of Bamlanivimab and Etesevimab together in high-risk ambulatory patients with COVID-19 and validation of the prognostic value of persistently high viral load","volume":"75","author":"Dougan","year":"2022","journal-title":"Clin Infect Dis"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1056\/nejmoa2108163","article-title":"REGEN-COV antibody combination and outcomes in outpatients with Covid-19","volume":"385","author":"Weinreich","year":"2021","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1001\/jama.2022.2832","article-title":"Effect of Sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19: a randomized clinical trial","volume":"327","author":"Gupta","year":"2022","journal-title":"JAMA"},{"volume-title":"Bamlanivimab emergency use authorization 090 approval letter","year":"2020","key":"ref5"},{"article-title":"Maximizing the benefit of COVID-19 therapeutics: considerations for state public health officials","year":"2022","author":"Greene","key":"ref6"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.5811\/westjem.2020.7.48217","article-title":"Development and usability testing of a web-based COVID-19 self-triage platform. Western","volume":"21","author":"Schrager","year":"2020","journal-title":"J Emerg Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.2105\/AJPH.2017.303882","article-title":"Ethical guidance for disaster response, specifically around crisis standards of care: a systematic review","volume":"107","author":"Leider","year":"2017","journal-title":"Am J Public Health"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"10.31478\/202108e","DOI":"10.31478\/202108e","article-title":"Crisis standards of care and COVID-19: what did we learn? How do we ensure equity? What should we do?","volume":"2021","author":"Hick","year":"2021","journal-title":"NAM Perspect"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1136\/emermed-2020-209792","article-title":"Online forward triage during the COVID-19 outbreak","volume":"38","author":"Hautz","year":"2021","journal-title":"Emerg Med J"},{"volume-title":"Distribution of Bamlanivimab by jurisdiction, November 2020 through march 2021","year":"2021","key":"ref11"},{"volume-title":"Distribution of REGEN-COV by jurisdiction, November 2020 through February 2021","year":"2021","key":"ref12"},{"volume-title":"Crisis standards of care: An overview of catastrophic planning in Minnesota","year":"2019","key":"ref13"},{"volume-title":"Minnesota pandemic ethics project","year":"","key":"ref14"},{"volume-title":"Ethical considerations - crisis standards of care","year":"","key":"ref15"},{"volume-title":"Operational guidance for monoclonal antibodies","year":"2022","key":"ref16"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1001\/jama.2022.1243","article-title":"Anti\u2013SARS-CoV-2 monoclonal antibody distribution to high-risk Medicare beneficiaries, 2020-2021","volume":"327","author":"Behr","year":"2022","journal-title":"JAMA"},{"year":"","key":"ref18","article-title":"Slow uptake in Minnesota for promising new COVID-19 therapy"},{"volume-title":"FDA limits use of certain monoclonal antibodies to treat COVID-19 due to the omicron variant","year":"","key":"ref19"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1093\/infdis\/jiab570","article-title":"Monoclonal antibody treatment of breakthrough COVID-19 in fully vaccinated individuals with high-risk comorbidities","volume":"225","author":"Bierle","year":"2022","journal-title":"J Infect Dis"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.mayocp.2021.11.017","article-title":"Clinical prioritization of Antispike monoclonal antibody treatment of mild to moderate COVID-19","volume":"97","author":"Razonable","year":"2022","journal-title":"Mayo Clin Proc"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/infdis\/jiac206","article-title":"Real-world evidence of the neutralizing monoclonal antibody Sotrovimab for preventing hospitalization and mortality in COVID-19 outpatients","volume":"226","author":"Aggarwal","year":"2022","journal-title":"J Infect Dis"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"ofab331","DOI":"10.1093\/ofid\/ofab331","article-title":"Real-world effectiveness and tolerability of monoclonal antibody therapy for ambulatory patients with early COVID-19","volume":"8","author":"Webb","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"ofab254","DOI":"10.1093\/ofid\/ofab254","article-title":"Impact of Bamlanivimab monoclonal antibody treatment on hospitalization and mortality among nonhospitalized adults with severe acute respiratory syndrome coronavirus 2 infection","volume":"8","author":"Bariola","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"ofab398","DOI":"10.1093\/ofid\/ofab398","article-title":"Real-world effect of monoclonal antibody treatment in COVID-19 patients in a diverse population in the United States","volume":"8","author":"Rainwater-Lovett","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"ofac204","DOI":"10.1093\/ofid\/ofac204","article-title":"Outcomes of B-cell-depleted patients with coronavirus disease 2019 treated with Antispike monoclonal antibodies","volume":"9","author":"Yetmar","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"e13901","DOI":"10.1111\/tid.13901","article-title":"Outcomes of bebtelovimab and sotrovimab treatment of solid organ transplant recipients with mild-to-moderate coronavirus disease 2019 during the omicron epoch","volume":"24","author":"Yetmar","year":"2022","journal-title":"Transpl Infect Dis"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1093\/cid\/ciac324","article-title":"Impact of vaccination and early monoclonal antibody therapy on coronavirus disease 2019 (COVID-19) outcomes in organ transplant recipients during the omicron wave","volume":"75","author":"Solera","year":"2022","journal-title":"Clin Infect Dis"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s11524-020-00508-9","article-title":"The expanding digital divide: digital health access inequities during the COVID-19 pandemic in new York City","volume":"98","author":"Eruchalu","year":"2021","journal-title":"J Urban Health"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1089\/pop.2020.0186","article-title":"Health inequalities in the use of telehealth in the United States in the Lens of COVID-19","volume":"23","author":"Jaffe","year":"2020","journal-title":"Popul Health Manag"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2023.1226935\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T21:07:32Z","timestamp":1701551252000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2023.1226935\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,28]]},"references-count":30,"alternative-id":["10.3389\/fpubh.2023.1226935"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2023.1226935","relation":{},"ISSN":["2296-2565"],"issn-type":[{"type":"electronic","value":"2296-2565"}],"subject":[],"published":{"date-parts":[[2023,11,28]]},"article-number":"1226935"}}